Area Director - Mid Atlantic
Glaukos, Washington, DC, Remote
Business DevelopmentBachelor RequiredExecutive Director
Glaukos, Washington, DC, Remote
The Interventional Business Manager (iBM) Director will lead a high-performing field team responsible for driving growth and execution across the interventional glaucoma portfolio. This role is pivotal in achieving revenue targets, shaping regional business strategy, and elevating field performance within a defined U.S. area.
Working cross-functionally with Interventional Glaucoma, Corneal Health, Practice Integration, Strategic Accounts, and Market Access, the Director will ensure alignment across initiatives and foster a culture of collaboration, accountability, and results.
This position represents a critical leadership opportunity to drive growth within Glaukos. The iBM Director will shape field execution, strengthen customer partnerships, and advance our mission to deliver innovative ophthalmic solutions that improve patient care.
We believe great talent deserves great rewards. The base salary range for this position reflects a good-faith estimate of what we reasonably expect to pay for this role at the time of posting. Actual compensation will be based on a variety of factors, including but not limited to the specific role, candidate’s relevant knowledge and experience, education, skills, internal equity, and geographic location. In addition, all full-time employees are eligible to participate in short term incentive opportunities (bonus or commission), RSU grants, Employee Stock Purchase Plan (ESPP) and a comprehensive suite of benefits designed to support health, happiness, and growth—inside and outside of work.
Generous. Innovative. Leadership-driven. Family-oriented. Socially responsible.
Founded in 1998, Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
Our mission at Glaukos is to truly transform vision by pioneering novel, dropless therapies that can meaningfully advance the standard of care and improve the lives of patients suffering from chronic, sight-threatening eye diseases.
Innovation is at the core of everything we do, and we are resolute in our commitment to challenge conventional thinking with new treatment alternatives that are supported by real science, robust clinical evidence, and an unrelenting focus on patients.
Our constant pursuit of game-changing technologies that disrupt legacy treatment paradigms is encapsulated in the Glaukos mantra “We’ll Go First,” which articulates our willingness to take chances, our determination to forge new ground, and our commitment to continuous improvement in all that we do.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is in Aliso Viejo, California with additional locations in San Clemente, California, and Burlington, Massachusetts.
Glaukos Corporation is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex including sexual orientation and gender identity, national origin, disability, protected Veteran Status, or any other characteristic protected by applicable federal, state, or local law.
All offers of employment are contingent upon the successful completion of a background check, including successfully passing a drug screen, based on the position and local regulations.
Glaukos is an ophthalmic medical technology and pharmaceutical company developing novel therapies and devices for glaucoma and other chronic eye diseases.
View company profile →